Deadline Soon: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitFeb 27, 2026 12:00 PM Eastern Standard Time# Deadline Soon: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitShare---LOS ANGELES--([BUSINESS WIRE])-- [The Law Offices of Frank R. Cruz] reminds investors of the upcoming March 2, 2026 deadline to participate as a lead plaintiff i ...

On February 17, 2026, Irenic Capital Management LP disclosed a new position in Integer Holdings (NYSE:ITGR), acquiring 1,263,663 shares in an estimated $99.11 million trade based on quarterly average pricing. What happened According to an SEC filing dated February 17, 2026, Irenic Capital Management LP established a new holding in Integer Holdings by acquiring 1,263,663 shares during the fourth quarter. The estimated value of the trade was $99.11 million, based on the average price for the period. The fu ...

Smith provided additional drivers behind the year’s earnings growth, noting operational improvements of $30 million (or $0.86 per share), reflecting higher volume, manufacturing efficiencies, operating expense management, and acquisition performance. Interest expense was $14 million lower year over year, adding $0.33 per share after tax, while foreign exchange pressure reduced adjusted net income by $2 million (or $0.07 per share). He also noted that a higher adjusted weighted average share count reduced ad ...

Company Overview - Integer Holdings is a leading global medical device outsource manufacturer with operations across the United States and internationally [6] - The company produces a broad portfolio of medical device components and finished devices, including cardiac rhythm management systems, neuromodulation products, vascular and orthopedic instruments, and customized battery solutions [9] - Integer Holdings serves multinational original equipment manufacturers (OEMs) in the healthcare sector, focusing on markets such as cardiac, neuromodulation, orthopedics, vascular, and advanced surgical devices [9] Financial Performance - As of February 17, 2026, Integer Holdings has a market capitalization of $3.07 billion, with a revenue of $1.83 billion and a net income of $86.90 million for the trailing twelve months (TTM) [4] - The company reported 8% full-year sales growth to $1.85 billion and 21% adjusted EPS growth to $6.40, with adjusted EBITDA reaching $402 million, up 12% year over year [10] - Integer Holdings generated $196 million in operating cash flow for 2025 [10] Recent Developments - On February 17, 2026, Newtyn Management disclosed a new position in Integer Holdings, acquiring 550,000 shares valued at approximately $43.14 million [1][2] - This new position accounts for 4.53% of Newtyn Management's 13F reportable assets under management as of December 31, 2025 [8] - As of the same date, shares of Integer Holdings were priced at $87.66, reflecting a decline of 37.9% over the past year, underperforming the S&P 500 by 49.75 percentage points [8] Debt and Guidance - Integer Holdings has a meaningful debt level of approximately $1.19 billion net, equating to about 3.0 times adjusted EBITDA [11] - Management is guiding for leverage between 2.5 and 3.5 times in 2026, with sales guidance implying flat to slightly down GAAP revenue, while adjusted earnings are expected to remain stable [11] Investment Considerations - The medical device manufacturing sector is characterized as steady, capital-intensive, and deeply embedded in customers' supply chains, making Integer Holdings' new position noteworthy despite its recent stock performance [10] - Long-term investors are encouraged to focus on organic growth, margin expansion, and deleveraging, as a well-executed strategy could lead to compounded growth for the company [12]

Core Insights - The company delivered 2025 sales and adjusted EPS at the high end of guidance, driven by 6% organic growth and 13% adjusted operating income expansion [1] - Strong performance in 2025 is attributed to new product ramps in electrophysiology, robust neurovascular demand, and successful integration of recent acquisitions [1] - A revenue headwind of 3% to 4% is identified for 2026 due to lower-than-anticipated market adoption of three specific new products in electrophysiology and neuromodulation [1] - The underlying core business remains healthy, with expected growth of 4% to 6% in 2026 when excluding the three underperforming products [1] - The company emphasizes a long-term strategy of engaging early in the design phase to accelerate customer innovation and simplify global supply chains [1] - A 300% increase in product development sales since 2017 is reported, viewed as a leading indicator for future commercial manufacturing contributions [1] - Commitment to a high-performance culture focused on the Integer Production System to drive operational excellence and margin expansion is affirmed [1]

Group 1 - The law firm Kahn Swick & Foti, LLC is investigating the proposed sale of Valaris Limited to Transocean Ltd, focusing on the adequacy of the price and process involved in the transaction [1] - Under the proposed terms, Valaris shareholders will receive 15.235 shares of Transocean stock for each share of Valaris they own [1] - KSF aims to determine if the consideration offered undervalues Valaris and whether the process leading to this transaction was adequate [1]

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of SunOpta Inc. to Refresco, focusing on whether the offered price of $6.50 per share adequately reflects the company's value and the process leading to this valuation [1]. Group 1: Proposed Sale Details - The proposed transaction involves SunOpta shareholders receiving $6.50 in cash for each share they own [1]. - The investigation aims to determine if the consideration is adequate or if it undervalues the company [1]. Group 2: Legal Rights and Contact Information - Shareholders who believe the transaction undervalues the company can discuss their legal rights with Kahn Swick & Foti, LLC without obligation or cost [1]. - Contact details for Kahn Swick & Foti include Managing Partner Lewis S. Kahn, who can be reached at 855-768-1857 or via email [1].

Core Viewpoint - F5, Inc. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for February 17, 2026, for investors who purchased securities during the class period from October 28, 2024, to October 27, 2025 [1] Company Overview - F5, Inc. is alleged to have misrepresented its revenue outlook and growth potential during the class period, creating a false impression of stability and minimizing risks associated with seasonality and macroeconomic factors [1] - The lawsuit claims that F5's optimistic statements about its security capabilities were misleading, as the company was experiencing a significant security incident that jeopardized its clients' security and future prospects [1] Legal Context - The Rosen Law Firm is leading the class action, emphasizing its experience and success in securities class actions, having recovered hundreds of millions for investors, including over $438 million in 2019 [1] - Investors who purchased F5 securities during the specified class period may be entitled to compensation without upfront costs, through a contingency fee arrangement [1]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market [7]. Allegation Details - The lawsuit claims that the company materially overstated its competitive position within the EP manufacturing market [3]. - It is alleged that despite the company's assertions of strong visibility into customer demand, there was a sustained deterioration in sales related to two of its EP devices [3]. - The company mischaracterized its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about its business and prospects [3]. Next Steps - Investors who purchased Integer shares between July 25, 2024, and October 22, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is February 9, 2026 [7].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about a class action lawsuit with a lead plaintiff deadline of February 9, 2026 [1]. Group 1: Class Action Details - Investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by February 9, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - The lawsuit asserts that the positive statements made by the defendants lacked a reasonable basis, leading to investor damages when the true details were revealed [5].